CALR and anemia: Regarding treatment‐related adverse events, the number of adverse events (anemia) was significantly higher in the CALR‐ET group (five patients [45.5%]) compared with the number of such events in the JAK2‐ET group (five patients [14.7%]; P = 0.037).